# Arvinas

Source: https://onco.cc/companies/arvinas/  
OnCo record `arvinas` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PROTAC pioneer whose vepdegestrant (Veppanu) became the first approved targeted protein degrader in May 2026; Rigel Pharmaceuticals now sells it under licence.

## Summary

Arvinas, based in New Haven and listed as ARVN, is the PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026. Founded on Craig Crews' PROTAC technology, it developed vepdegestrant, an oestrogen receptor degrader, with Pfizer; the FDA approved it as Veppanu on 1 May 2026 for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine therapy. Arvinas and Pfizer then licensed exclusive global rights to Rigel Pharmaceuticals, which took over the US launch; the licence took effect in June 2026 with a 70 million dollar upfront payment shared between Arvinas and Pfizer, and up to 320 million dollars in further milestones plus royalties. Its pipeline includes ARV-393 against BCL6 and ARV-102 against LRRK2 in neurology. OnCo links it to HR-positive, HER2-negative breast cancer, to PROTACs and molecular glues, to the bottleneck of undruggable drivers, and to ideas for an open degrader consortium and for destroying the truncated androgen receptor. Whether degraders can reach transcription factors that inhibitors never could is the open question the first approval makes urgent. Vepdegestrant has its own page.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: New Haven, CT
- Type: biotech
- Website: https://www.arvinas.com
- Ticker: ARVN

## Notes

- Freshened 29 October 2026 from Arvinas SEC 8-K filings of 1 May, 11 May and 11 June 2026. No acquisition of Arvinas was found.

## Sources

- Official website: https://www.arvinas.com
- FDA approval of Veppanu (SEC 8-K, May 2026): https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/arvn-20260501.htm
- Rigel licence agreement (SEC 8-K, May 2026): https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/arvn-20260511.htm
- Rigel licence effective (SEC 8-K, June 2026): https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Vepdegestrant](https://onco.cc/drugs/vepdegestrant/)
- companies: [5AM Ventures](https://onco.cc/companies/5am-ventures/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Rigel Pharmaceuticals](https://onco.cc/companies/rigel-pharmaceuticals/)
- trials: [A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07749586/), [A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation](https://onco.cc/trials/nct07023731/), [VERITAC-2](https://onco.cc/trials/veritac-2/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- ideas: [An open degrader consortium against every undruggable driver transcription factor](https://onco.cc/ideas/idea-moon-open-degrader-consortium/), [Destroy the truncated androgen receptor that hormone drugs cannot touch](https://onco.cc/ideas/idea-bio1-arv7-degrader/)

---
JSON: https://onco.cc/api/v1/entities/arvinas.json